Cingulate Inc. shared updates on its plans to respond to the FDA about the CTx-1301 drug.

Nov 10, 2026, 8:21 AM ETTrialRead the original at SEC EDGAR

Good for CING

Cingulate says it has nearly finished FDA-requested manufacturing work and expects to resend its drug application by January 2027. The earlier rejection and uncertain approval remain risks, but the FDA raised no safety or effectiveness concerns, making this progress encouraging.

CING · Cingulate Inc.

AI read · Good for CING

The AI's read

That progress moves Cingulate closer to another FDA review after the agency stopped the application over manufacturing information. The company says most requested work is done, and the FDA raised no concerns about the drug's safety or effectiveness. The earlier rejection still matters, and the company cannot promise a resubmission, approval, or launch.

Get alerts for CING

Follow Cingulate Inc. (CING) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CING

Free on the App Store and Google Play, or on the web.